Pregnancy Outcomes in Women with Multiple Sclerosis Who Had Exposure to Ocrelizumab: a Systematic Review of the Literature

Overview

Journal Maedica (Bucur)

Specialty General Medicine

Date 2025 Feb 20

PMID 39974450

Authors

Zahra Shahraki

Ali Zarrinnia

Fariba Askari

Mohsen Rastkar

Mahsa Ghajarzadeh

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the pooled prevalence of pregnancy-related issues in women who were exposed to Ocrelizumab before or during pregnancy.

Methods: PubMed, Scopus, EMBASE, Web of Science, Google Scholar, references and conference abstracts were comprehensively searched by two independent researchers. The search was conducted on 1 June 2023.

Results: A literature search revealed 320 records, of which 44 full-texts were evaluated and only five studies remained for the systematic review, among which one study was conducted in Australia, one in the United States, one in Canada and one in the United Kingdom. All eligible studies were conducted between 2017 and 2022. They included a number of patients ranging from 12 to 608, and totalized 1 305 participants and 1 306 pregnancies. The pooled prevalence of term delivery was 46% (95% CI 31-61%) (I²=94.5%, P<0.001). The pooled prevalence of abortion was 9% (95% CI 4-14%) (I²=80%, P<0.001). Three studies reported on the number of ectopic pregnancies. The pooled prevalence of ectopic pregnancies was 5% (95% CI 2-4%) (I²=60%, P<0.001). The pooled prevalence of major congenital malformations was 2% (95% CI 1-3%) (I²=0).

Conclusions: The results of this systematic review show that exposure to Ocrelizumab during conception is not associated with a higher frequency of preterm deliveries or major malformations.

References

Gingele S, Jacobus T, Konen F, Hummert M, Suhs K, Schwenkenbecher P . Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients. Cells. 2019; 8(1). PMC: 6356421. DOI: 10.3390/cells8010012. View

Rigau V, Mania A, Befort P, Carlander B, Jonquet O, Lassmann H . Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology. 2012; 79(22):2214-6. DOI: 10.1212/WNL.0b013e318275979d. View

Bar-Or A, Calabresi P, Arnold D, Arnlod D, Markowitz C, Shafer S . Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008; 63(3):395-400. DOI: 10.1002/ana.21363. View

Ma L, Wang Y, Yang Z, Huang D, Weng H, Zeng X . Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?. Mil Med Res. 2020; 7(1):7. PMC: 7049186. DOI: 10.1186/s40779-020-00238-8. View

Gitman V, Stavropoulos A, Saenz V, Pasquarelli N, Zecevic D, Devonshire V . Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in Canada: A descriptive analysis of real-world data. Mult Scler Relat Disord. 2022; 62:103792. DOI: 10.1016/j.msard.2022.103792. View

Chey S, Kermode A . Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis. Mult Scler J Exp Transl Clin. 2022; 8(1):20552173221085737. PMC: 8905230. DOI: 10.1177/20552173221085737. View

Hu Y, Nie H, Yu H, Qin C, Wu L, Tang Z . Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Autoimmun Rev. 2019; 18(5):542-548. DOI: 10.1016/j.autrev.2019.03.011. View

Kumpfel T, Thiel S, Meinl I, Ciplea A, Bayas A, Hoffmann F . Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany. Neurol Neuroimmunol Neuroinflamm. 2020; 8(1). PMC: 7757754. DOI: 10.1212/NXI.0000000000000913. View

Rozsa C . [Family planning in multiple sclerosis: conception, pregnancy, breastfeeding]. Ideggyogy Sz. 2020; 73(05-06):161-169. DOI: 10.18071/isz.73.0161. View

10.

Tedder T, Engel P . CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994; 15(9):450-4. DOI: 10.1016/0167-5699(94)90276-3. View

11.

Marousi S, Giannouli E, Karkanis I, Tagaris G, Karageorgiou C . Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?. Neurology. 2011; 76(15):1362-3. View

12.

Meinl I, Havla J, Hohlfeld R, Kumpfel T . Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. Mult Scler. 2017; 24(7):991-994. DOI: 10.1177/1352458517731913. View

13.

Kane S, Acquah L . Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2008; 104(1):228-33. DOI: 10.1038/ajg.2008.71. View

14.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V . Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018; 90(10):e823-e831. DOI: 10.1212/WNL.0000000000005067. View

15.

Barry B, Erwin A, Stevens J, Tornatore C . Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. Neurol Ther. 2019; 8(2):241-250. PMC: 6858914. DOI: 10.1007/s40120-019-00160-9. View

16.

Kappos L, Li D, Calabresi P, OConnor P, Bar-Or A, Barkhof F . Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011; 378(9805):1779-87. DOI: 10.1016/S0140-6736(11)61649-8. View

17.

Naismith R, Piccio L, Lyons J, Lauber J, Tutlam N, Parks B . Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010; 74(23):1860-7. PMC: 2882224. DOI: 10.1212/WNL.0b013e3181e24373. View

18.

Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E . Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2012; 5(1):22-33. PMC: 3564883. DOI: 10.4161/mabs.22771. View

19.

Calvo-Barreiro L, Eixarch H, Montalban X, Espejo C . Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. Autoimmun Rev. 2017; 17(2):165-174. DOI: 10.1016/j.autrev.2017.11.019. View

20.

Montalban X, Hauser S, Kappos L, Arnold D, Bar-Or A, Comi G . Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016; 376(3):209-220. DOI: 10.1056/NEJMoa1606468. View